BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 11505214)

  • 1. Quantitative studies of bone using (18)F-fluoride and (99m)Tc-methylene diphosphonate: evaluation of renal and whole-blood kinetics.
    Park-Holohan SJ; Blake GM; Fogelman I
    Nucl Med Commun; 2001 Sep; 22(9):1037-44. PubMed ID: 11505214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative studies of bone in postmenopausal women using (18)F-fluoride and (99m)Tc-methylene diphosphonate.
    Blake GM; Park-Holohan SJ; Fogelman I
    J Nucl Med; 2002 Mar; 43(3):338-45. PubMed ID: 11884493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A direct in vivo measurement of 99mTc-methylene diphosphonate protein binding.
    Blake GM; Moore AE; Park-Holohan SJ; Fogelman I
    Nucl Med Commun; 2003 Jul; 24(7):829-35. PubMed ID: 12813203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative measurements of bone remodeling using 99mTc-methylene diphosphonate bone scans and blood sampling.
    Moore AE; Blake GM; Fogelman I
    J Nucl Med; 2008 Mar; 49(3):375-82. PubMed ID: 18287266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of ultrafiltration as a method of measuring free 99mTc-MDP.
    Moore AE; Hain SF; Blake GM; Fogelman I
    J Nucl Med; 2003 Jun; 44(6):891-7. PubMed ID: 12791815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of a blood-sampling method for the measurement of 99mTc-methylene diphosphonate skeletal plasma clearance.
    Moore AE; Blake GM; Fogelman I
    J Nucl Med; 2006 Apr; 47(4):581-6. PubMed ID: 16595490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on diphosphonate kinetics. Part I: Evaluation of plasma elimination curves during 24 h.
    Hyldstrup L; McNair P; Ring P; Henriksen O
    Eur J Nucl Med; 1987; 12(12):581-4. PubMed ID: 3107990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study to determine the dependence of 99mTc-MDP protein binding on plasma clearance and serum albumin concentration.
    Moore AE; Blake GM; Fogelman I
    Nucl Med Commun; 2007 Mar; 28(3):187-92. PubMed ID: 17264777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radionuclide studies of bone metabolism: do bone uptake and bone plasma clearance provide equivalent measurements of bone turnover?
    Blake GM; Siddique M; Frost ML; Moore AE; Fogelman I
    Bone; 2011 Sep; 49(3):537-42. PubMed ID: 21689803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on diphosphonate kinetics. Part II: Whole body bone uptake rate during constant infusion--a refined index of bone metabolism.
    Hyldstrup L; McNair P; Ring P; Henriksen O
    Eur J Nucl Med; 1987; 12(12):585-8. PubMed ID: 3107991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 18F fluoride PET/CT and 99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma.
    Chakraborty D; Bhattacharya A; Mete UK; Mittal BR
    Clin Nucl Med; 2013 Aug; 38(8):616-21. PubMed ID: 23603596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative studies of bone using (99m)Tc-methylene diphosphonate skeletal plasma clearance.
    Blake GM; Moore AE; Fogelman I
    Semin Nucl Med; 2009 Nov; 39(6):369-79. PubMed ID: 19801217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromium 51 EDTA/technetium 99m MDP plasma ratio to measure total skeletal function.
    Nisbet AP; Edwards S; Lazarus CR; Malamitsi J; Maisey MN; Mashiter GD; Winn PJ
    Br J Radiol; 1984 Aug; 57(680):677-80. PubMed ID: 6235885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conventional measurements of GFR using 51Cr-EDTA overestimate true renal clearance by 10 percent.
    Moore AE; Park-Holohan SJ; Blake GM; Fogelman I
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):4-8. PubMed ID: 12483403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of simultaneous plasma clearance of
    Andersen TB; Jødal L; Nielsen NS; Petersen LJ
    Scand J Clin Lab Invest; 2019 Nov; 79(7):463-467. PubMed ID: 31502901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of regional changes in skeletal metabolism following 3 and 18 months of teriparatide treatment.
    Moore AE; Blake GM; Taylor KA; Rana AE; Wong M; Chen P; Fogelman I
    J Bone Miner Res; 2010 May; 25(5):960-7. PubMed ID: 19929434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal and extrarenal clearance of 99mTc-MAG3: a comparison with 125I-OIH and 51Cr-EDTA in patients representing all levels of glomerular filtration rate.
    Rehling M; Nielsen BV; Pedersen EB; Nielsen LE; Hansen HE; Bacher T
    Eur J Nucl Med; 1995 Dec; 22(12):1379-84. PubMed ID: 8586082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes observed in radionuclide bone scans during and after teriparatide treatment for osteoporosis.
    Moore AE; Blake GM; Taylor KA; Ruff VA; Rana AE; Wan X; Fogelman I
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39(2):326-36. PubMed ID: 22057627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients.
    Yen RF; Chen CY; Cheng MF; Wu YW; Shiau YC; Wu K; Hong RL; Yu CJ; Wang KL; Yang RS
    Nucl Med Commun; 2010 Jul; 31(7):637-45. PubMed ID: 20389259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.